COMPANY PROFILE

Zhimeng Biopharma

Clinical-stage biopharmaceutical company developing small-molecule drugs for chronic hepatitis B and central nervous system disorders

Pudong, ChinaFounded 2017Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Zhimeng Biopharma

Shanghai Zhimeng Biopharma Inc. (Zhimeng Biopharma, 挚盟医药) is a clinical-stage biopharmaceutical company based in Shanghai's Zhangjiang Hi-Tech Park, developing novel small-molecule therapeutics for chronic hepatitis B (CHB) and central nervous system (CNS) disorders. Founded in 2017 by pharmaceutical industry veterans including co-founder and CEO Huanming Chen, the company operates an innovative drug R&D platform spanning liver diseases and neurological and psychiatric conditions.

In chronic hepatitis B, Zhimeng targets multiple stages of the hepatitis B virus (HBV) life cycle: ZM-H1505R, a type II capsid assembly modulator designated a Breakthrough Therapy by China's Center for Drug Evaluation (CDE) in January 2025, suppresses viral replication; CB06-036, an oral TLR8 agonist aimed at restoring host immune responses, was out-licensed globally to GSK. In CNS, the KCNQ2/3 potassium channel opener CB03-154, granted FDA Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) in 2023, is in clinical development for refractory epilepsy, neuropathic pain, ALS, major depressive disorder and bipolar disorder.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Pudong, China
Employees: 7
Open positions: None listed
Dealroom signal: 40.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Nov 2021	$48M	$193M	Dyee Capital · Dawu Venture Capital · Advantech Capital · Fortune Venture	↗
SERIES AOther financing	Nov 2020	$35M	$710M	Photon Fund · State Development & Investment Corporation (SDIC) · Oceanpine Capital	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Zhimeng Biopharma website traffic

Latest recorded traffic for Zhimeng Biopharma is 380 monthly website visits, down 35.6% over the last three months. Zhimeng Biopharma's team declined 12.5% over the past year.

Latest monthly visits380 3-month web change-35.6% 1-year team growth-12.5%

Monthly website visitsFeb 2020–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
CGCSPC Pharmaceutical GroupCSPC Pharmaceutical Group is a pharmaceutical group in China	Shijiazhuang, China	Operational
WAWaveBreakSmall-molecule therapeutics for neurodegenerative diseases	Cambridge, United Kingdom	Operational
FBFreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine	Barcelona, Spain	Operational
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational
RTRewind TherapeuticsFirst-in-class remyelinating therapies for myelin-related diseases	Belgium, United States	Operational
APAudioCure PharmaPharmaceutical company with a focus on hearing impairments	Berlin, Germany	Operational